Elizabeth A Raetz Selected Research

pegaspargase (Oncaspar)

10/2021	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
1/2021	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
10/2020	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
10/2020	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
1/2019	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.
10/2018	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
1/2018	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
1/2016	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
7/2015	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elizabeth A Raetz Research Topics

Disease

58	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 04/2005
13	Neoplasms (Cancer) 01/2022 - 08/2003
12	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 08/2006
11	Leukemia 01/2022 - 10/2002
7	Residual Neoplasm 04/2021 - 06/2011
5	Hypersensitivity (Allergy) 01/2021 - 10/2010
5	Philadelphia Chromosome 01/2021 - 09/2014
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2022 - 01/2007
4	Infections 01/2021 - 08/2008
3	Lymphoma (Lymphomas) 01/2022 - 08/2014
3	Pancreatitis 01/2018 - 10/2010
2	Sepsis (Septicemia) 04/2022 - 01/2021
2	Cytopenia 01/2022 - 01/2018
2	Genetic Predisposition to Disease (Genetic Predisposition) 11/2019 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 07/2015
2	Osteonecrosis (Kienbock's Disease) 10/2016 - 10/2015
1	Tics (Tic) 04/2022
1	Hyperbilirubinemia 01/2022
1	Bacteremia 10/2021
1	Neutropenia 10/2021
1	Disease Progression 01/2021
1	Down Syndrome (Down's Syndrome) 01/2021
1	Febrile Neutropenia 01/2021
1	Mucositis 01/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2020
1	Glucosephosphate Dehydrogenase Deficiency 01/2019
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2019
1	Multiple Myeloma 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018
1	Brain Ischemia (Cerebral Ischemia) 10/2015
1	Embolism and Thrombosis 10/2015

Drug/Important Bio-Agent (IBA)

9	pegaspargase (Oncaspar)FDA Link 10/2021 - 07/2015
9	Asparaginase (Elspar)FDA Link 01/2021 - 10/2010
8	Biological ProductsIBA 04/2021 - 10/2002
7	Methotrexate (Mexate)FDA LinkGeneric 10/2020 - 07/2015
4	Proteins (Proteins, Gene)FDA Link 06/2021 - 09/2002
4	Pharmaceutical PreparationsIBA 08/2014 - 04/2005
3	Inotuzumab OzogamicinIBA 01/2022 - 01/2019
3	ChromatinIBA 06/2021 - 07/2014
3	nelarabine (506U78)FDA Link 10/2020 - 07/2015
3	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 05/2006
3	Phosphotransferases (Kinase)IBA 12/2019 - 09/2014
3	RNA (Ribonucleic Acid)IBA 07/2015 - 03/2013
2	Bortezomib (Velcade)FDA Link 01/2022 - 01/2019
2	lestaurtinibIBA 05/2021 - 01/2021
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 10/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 08/2014
2	Leucovorin (Folinic Acid)FDA Link 10/2020 - 10/2018
2	Cytokine Receptors (Cytokine Receptor)IBA 12/2019 - 01/2017
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019 - 08/2017
2	Monoclonal AntibodiesIBA 01/2018 - 08/2008
2	AntibodiesIBA 01/2018 - 08/2014
2	epratuzumabIBA 07/2015 - 08/2008
2	ProteomeIBA 01/2007 - 05/2006
1	insulin receptor-related receptor (IRR)IBA 04/2022
1	ribociclibIBA 01/2022
1	palbociclibIBA 01/2022
1	Cytotoxins (Cytolysins)IBA 01/2022
1	Drug CombinationsIBA 01/2022
1	Cyclin DIBA 01/2022
1	Cyclin D3IBA 01/2022
1	Proteasome InhibitorsIBA 01/2022
1	Antigen Receptors (Antigen Receptor)IBA 04/2021
1	Vincristine (Oncovin)FDA LinkGeneric 01/2021
1	AntigensIBA 01/2021
1	HLA-DQB1 antigen (HLA DQB1)IBA 01/2021
1	blinatumomabIBA 01/2021
1	ElementsIBA 12/2019
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019
1	Essential Amino AcidsIBA 01/2019
1	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 01/2019
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2019
1	AnthracyclinesIBA 01/2019
1	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 01/2019
1	AsparagineIBA 01/2019
1	methylervineIBA 10/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	Clofarabine (Clolar)FDA Link 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	daratumumabIBA 01/2018
1	Carboxypeptidases A (Carboxypeptidase A)IBA 01/2016
1	purineIBA 01/2016
1	Glutamate Receptors (Glutamate Receptor)IBA 10/2015
1	GlucocorticoidsIBA 10/2015
1	calaspargase pegolIBA 12/2014
1	Transcription Factors (Transcription Factor)IBA 09/2014
1	Tyrosine Kinase InhibitorsIBA 09/2014

Therapy/Procedure

33	Therapeutics 04/2022 - 04/2005
23	Drug Therapy (Chemotherapy) 01/2022 - 08/2008
4	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2019
2	Cranial Irradiation 10/2018 - 01/2018
1	Catheters 04/2022
1	Treatment Delay 10/2021
1	Immunotherapy 01/2018
1	Remission Induction 01/2017